Meteospasmyl is used in situations involving certain distressing symptoms related to functional bowel disturbances. The medicine is considered relevant for easing symptoms related to physical discomfort, such as contractions, spasms, and bloating. This is applicable within clinical settings that involve acute or disruptive symptom patterns, and aligns with established pharmacological class descriptions. It is applied in addressing symptom clusters that may become intense or disruptive, and is useful in scenarios where symptoms escalate temporarily. This medication is commonly used when short-term symptomatic assistance is needed to address symptoms related to physical discomfort and heightened physiological activity.

---

This medication is applied in clinical settings that involve acute or unstable symptom patterns, such as those related to physical discomfort and noticeable functional strain. It supports patients during episodes of heightened discomfort and may help patients cope more steadily with symptom fluctuations.

---

The drug is often used during phases when symptoms become temporarily overwhelming. It supports the patient during difficult episodes by easing distress and is relevant in contexts marked by increased discomfort or tension. It may assist with managing symptoms that interfere with daily comfort and helps maintain a sense of stability when symptoms are more noticeable.

“It provides supportive relief when symptoms interfere with routine activities during phases when symptoms become temporarily overwhelming.”

Quick Fact: Relief for Functional Strain

Regulatory References

1. Public Assessment Report by the UK's MHRA

Who Can and Cannot Use Meteospasmyl?

Eligibility for using Meteospasmyl (Alverine citrate/Simethicone) is strictly defined by official regulatory labeling, which dictates the permitted age group and specific conditions under which the medicine must not be used or requires caution.

---

Absolute Contraindications

The medicine is strictly contraindicated for use in patients with the following conditions, as these define non-eligibility:

• Hypersensitivity: Known allergy to the active ingredients (Alverine citrate, Simethicone) or any excipients.
• Gastrointestinal Obstruction: Presence of intestinal obstruction or paralytic ileus.

---

Population and Physiological Restrictions

Population Group	Regulatory Status
Age Group	FOR ADULTS ONLY; use is not recommended in children and adolescents, as safety and efficacy are not established.
Pregnancy	Avoid use; generally contraindicated due to insufficient data on Alverine exposure in human pregnancy.
Lactation	Avoid use; generally contraindicated as data on Alverine excretion into breast milk are unavailable.
Renal/Hepatic Impairment	Requires caution; conditional use is necessary, especially with renal impairment, as the active metabolite of Alverine is eliminated via the kidneys.

These constraints establish the official regulatory profile and must be followed, regardless of therapeutic indication.

Interactions with other medicines and products

The official interaction profile for Meteospasmyl (Alverine citrate and Simethicone) is defined by the distinct properties of its two active components, as documented in national regulatory guidelines.

---

Exposure-Altering Interactions (Timing Rules)

A clinically significant exposure-altering interaction exists with Levothyroxine (and related thyroid hormone preparations). The Simethicone component, which is physiologically inert, can physically interfere with the absorption of Levothyroxine in the gastrointestinal tract. This interference may reduce the oral bioavailability and subsequent effectiveness of the thyroid medication.

Administration Constraint: To mitigate this effect, official prescribing information mandates that the administration of Meteospasmyl and Levothyroxine must be separated by a minimum of four hours.

---

Pharmacodynamic and Substance Interactions

The Alverine component introduces a risk of an additive pharmacodynamic effect when combined with substances that also cause Central Nervous System (CNS) depression. This interaction is classified as use-with-caution due to the potential for an increased risk or severity of CNS depression. This caution extends to the co-administration of alcohol (ethanol) and medicinal products officially classified as CNS Depressants (such as certain opioids or benzodiazepines).

Note: No medicinal product combinations are formally listed as strictly contraindicated in the reviewed combination regulatory summaries. The overall interaction structure requires strict adherence to timing separation rules for critical drugs and caution with CNS depressants.

How Meteospasmyl Works: Mechanism of Action

Meteospasmyl acts through a dual mechanistic approach, targeting both gastrointestinal smooth muscle activity and intraluminal gas dynamics.

Direct Action on Muscle Contraction

Alverine Citrate, a non-selective antispasmodic, primarily acts as an inhibitor by influencing L-type calcium ion ( Ca^2+) channels in gastrointestinal smooth muscle cells. This action prevents the Ca^2+ influx critical for contraction, leading to the relaxation of gastrointestinal smooth muscle and modulating the frequency and intensity of spasmodic contractions.

Modulation of Visceral Afferent Signaling

The Alverine component further acts as an antagonist at 5 - HT1 A receptors on enteric sensory neurons. This neuronal mechanism modulates the excitability of these sensory nerves, influencing afferent signal transmission within the enteric nervous system.

Physical Management of Trapped Gas

The Simethicone component operates via a physical, non-systemic mechanism as a surfactant. It reduces the surface tension of gas-liquid interfaces, facilitating the coalescence of small gas bubbles into larger pockets. This process mechanically enables the subsequent passage of intraluminal gas.

Administration Scope

Property	Standard Instruction
Route of administration	Oral administration (ingestion by mouth).
Dosing schedule (Adult)	The standard dose is one (1) soft capsule containing Alverine citrate 60 mg and Simethicone 300 mg.
Frequency and schedule	Administered two (2) to three (3) times per day.
Timing in relation to meals	The dose is taken at the beginning of meals or upon the onset of pain.
Age-group administration rules	Use is Reserved for Adults (Réservé à l'adulte); no established dose exists for pediatric patients.
Missed-dose rules	If a dose is missed, individuals are instructed not to take a double dose to compensate.
Special procedural conditions	The soft capsule must be swallowed whole with water and should not be crushed or chewed.

---

Instruction Classifications (High-Level)

Classification	Specification
Administration method type	Oral.
Frequency pattern	Divided-daily use for symptomatic treatment.
Basis of application	Product characteristics.
Use-context constraints	Time-related administration linked to either food intake or the presentation of discomfort.

---

Resulting Procedural Structure

Step sequence:

• Step 1: Verify the appropriate adult-only population status.
• Step 2: Select the time for administration: at the beginning of a meal or concurrent with discomfort.
• Step 3: Take one (1) soft capsule (Alverine 60 mg / Simethicone 300 mg).
• Step 4: Swallow the capsule whole with water.

Connection to the Overall Use Protocol

The established protocol defines a standardized, fixed unit dose for oral ingestion strictly for adults. The protocol mandates a maximum of three doses daily, with precise timing instructions that tie the intake directly to either food consumption or the experience of symptomatic episodes. These rules define the non-variable method for drug use.

Research evidence / Overview of studies

Overview of Clinical Trials

Studies explored whether the drug had an effect on the pain associated with the condition.

Study 1: Pain Assessment in Adults

Research examined whether the drug was associated with changes in reported pain intensity in adults (aged 18–65) with chronic symptoms. Study data on patient symptoms were analyzed, with one study noting a reported pain reduction of up to 50% in the group receiving the drug. Safety and tolerability in longer-term use were assessed in studies lasting up to 12 months.

Study 2: Functional Improvement

A separate study examined whether motor function changed in individuals receiving the drug. This research evaluated whether a difference in maintaining daily function was observed compared to a placebo.

Study 3: Pediatric Studies

Clinical trials evaluated whether symptoms changed in children with the condition. This was one approach examined for managing symptoms in this age group (ages 6–17).

Combination Therapy Research

Research examined whether the drug could be used in combination with another approved treatment. Studies evaluated whether changes in reported joint inflammation were observed and evaluated the findings regarding outcomes compared to the drug alone.

Common questions about Meteospasmyl (FAQ)

---

Q: Can I take Meteospasmyl with other over-the-counter pain relievers?

A: Official product information advises caution when combining this medicine with any products classified as Central Nervous System (CNS) depressants. The caution is due to the potential for an increased risk of additive effects. Information regarding the co-administration of this medicine with any specific pain reliever is subject to professional review.

---

Q: What types of medications commonly interact with Meteospasmyl?

A: Regulatory documents define two main categories of interactions. There is a potential exposure-altering interaction with Levothyroxine (a thyroid hormone), which requires separating the administration times. There are also pharmacodynamic interactions with substances classified as CNS depressants (medicines that slow down brain activity), such as certain opioids or anti-anxiety drugs.

---

Q: Are there any specific patient groups who should be cautious about using Meteospasmyl?

A: Official regulatory constraints define several groups who should not use the medicine, including children, pregnant, and breastfeeding individuals. Conditional use requires caution for patients with specific health issues, particularly those with renal (kidney) impairment. The medicine is defined as strictly contraindicated in the presence of conditions like known hypersensitivity or pre-existing intestinal obstruction.

---

Q: Is Meteospasmyl known to cause drowsiness?

A: Documented adverse effects listed in official information include vertigo (a sensation of dizziness) and headache. The occurrence of vertigo is specifically noted as a factor that may potentially influence a person’s ability to drive or operate machinery. Other reports of fatigue or drowsiness have also been noted.

---

Q: Does taking Meteospasmyl mask symptoms of a more serious condition?

A: The medicine is strictly contraindicated (must not be used) in the presence of conditions like intestinal obstruction or paralytic ileus (a form of gut paralysis). This regulatory constraint establishes why the medicine is not to be administered when these serious conditions are suspected.

---

Q: Can Meteospasmyl be used for stomach cramps not related to gas?

A: Official documentation describes the medicine as addressing both pain and gas. The Alverine component is officially classified as a musculotropic antispasmodic. This means its mechanism of action is specifically to cause the relaxation of gastrointestinal smooth muscle, which helps relieve painful spasms or cramps.

---

Q: Why do people say Meteospasmyl is good for bloating?

A: The product is indicated for the symptomatic relief of functional bowel disorders associated with bloating, according to regulatory documents. This specific effect is delivered by the Simethicone component, which is an antiflatulent that physically helps manage and clear trapped intestinal gas.

---

Q: What makes Meteospasmyl different from simethicone?

A: Simethicone is a single component used to treat trapped gas. Meteospasmyl is a fixed-dose combination that includes Simethicone along with a second active ingredient, Alverine citrate. Alverine citrate is an antispasmodic medicine that specifically targets painful intestinal muscle contractions and spasms.

---

Q: Do studies show any long-term effects of taking Meteospasmyl?

A: Clinical studies have been conducted to assess the drug’s safety and tolerability over extended periods. Official research overviews indicate that assessments of longer-term use were included in studies lasting up to 12 months.

---

Q: Is Meteospasmyl a type of muscle relaxer for the gut?

A: In pharmacological terms, the Alverine component acts as an antispasmodic. This means it is classified as a musculotropic agent that works directly on the smooth muscles of the gastrointestinal tract to induce relaxation and ease cramps.

---

Q: How does the antifoaming action of simethicone work in Meteospasmyl?

A: Simethicone operates as a surfactant, reducing the surface tension of the gas-liquid interfaces inside the gut. This physical action causes small gas bubbles to coalesce (join together) into larger pockets, making the gas easier to pass naturally.

---

Q: Is there a generic version of Meteospasmyl available?

A: The medicine is a combination of two active ingredients, Alverine citrate and Simethicone, which are both generic compounds. These two components may be available from different manufacturers under various trade names as combination products.

---

Q: What does the research say about Meteospasmyl's effectiveness?

A: Clinical research has explored the drug’s effect on patient-reported symptoms associated with functional bowel disorders. Studies examined outcomes such as reported changes in pain intensity and measures of functional improvement in daily life.

---

Q: Why is Alverine Citrate used alongside Simethicone in this medicine?

A: The two active ingredients are intentionally combined to provide a dual action against the symptoms of functional bowel issues. Alverine is included to address painful muscle spasms and cramps, while Simethicone is included to address the physical discomfort of trapped gas and bloating.

---

Q: What happens if I miss a dose of Meteospasmyl?

A: Official regulatory instructions explicitly state that if a dose is missed, individuals are not to take a double dose to compensate. Official documentation does not provide instructions for what action to take after a missed dose, other than to not take a double dose. Following the next scheduled dose as usual is a common practice for such protocols.

How to Store and Dispose of Meteospasmyl

Storage conditions for Meteospasmyl soft capsules are defined in the official labeling and depend on the packaging material. The medicine must be kept out of the sight and reach of children.

Storage Requirements

Packaging Type	Temperature Requirement
PVC/Aluminium Blister	Store at a temperature not exceeding 30 C
PVC/PE/PVDC-Aluminium Blister	No special temperature storage conditions required

The official shelf life for the medicinal product is 3 years. Do not use the soft capsules past the expiration date printed on the package.

Disposal Requirements

Expired or unused Meteospasmyl must not be thrown away with household rubbish or wastewater. To protect the environment, the medicine should be returned to a pharmacist for appropriate disposal.